Abstract
Background Heart failure with preserved ejection fraction (HFpEF) is a complex disease characterized by metabolic disturbances that can have various pathophysiological implications.
Methods Data were collected from a prospective cohort consisting of 30 HFpEF participants and 30 healthy controls, matched by gender and age. untargeted metabolomic profiling UHPLC-MS/MS was performed on Venous blood. The analyses aimed to reveal the differences in plasma metabolic characteristics between HFpEF participants and healthy controls using untargeted metabolomics. Initial steps included Principal Components Analysis (PCA), Partial Least Squares-Discriminant Analysis (PLS-DA), and hierarchical clustering analysis to detect differing compounds groups. Subsequently, Receiver Operating Characteristic (ROC) curve analysis and pathway analysis of the different metabolites. Finally, we performed pathway enrichment analysis to identify significantly dysregulated processes.
Results A total of 124 significantly different compounds were selected based on criteria of Variable Importance in Projection (VIP) > 1.0, Fold Change (FC) > 1.2 or FC < 0.833, and P-value < 0.05. Compared to healthy control group, the most altered metabolites in HFpEF were lipids and lipid-like molecules. KEGG enrichment and pathway impact analysis highlight the enrichment of these differentially expressed metabolites primarily in tryptophan metabolism. Hierarchical clustering results, showed varying compound levels between the two groups. ROC curve results, revealed Cytosine and 1,2-dihydroxyheptadec-16-yn-4-yl having higher AUC values.
Conclusions Significant differences were observed in plasma metabolic profiles between HFpEF patients and healthy subjects using UHPLC-MS/MS. Cytosine appeared a potential biomarker. Tryptophan metabolism may be a novel metabolic pathway of HFpEF.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Key R&D Program of Xinjiang Uygur Autonomous Region [Grant No. 2022B03023-4].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study received approval from the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University. informed consent was obtained from each participant.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors